Getinge 2022 Annual Report
Getinge 2022 Annual Report
NOTE 27
Acquisition of operations
Net assets acquired, SEK M
Intangible assets
Tangible assets
Deferred tax assets
Inventories
Accounts receivables
Other current receivables
Cash and cash equivalents
Other provisions
Other interest-bearing liabilities
Deferred tax liabilities
Accounts payable
Other non-interest-bearing liabilities
Identifiable net assets
Goodwill
Total purchase prices
Add/Less:
Additional purchase prices and other adjustments
Acquisition of shares from non-controlling interests
Unpaid purchase prices
Cash and cash equivalents in the acquired operations
Impact on the Group's cash and cash equivalents
Introduction
Strategy
Corporate Governance
Annual Report
Sustainability Report
Other information
Contents
2022
141
2021
125
2
2
18
12
34
12
7
7
3
18
1
0
-15
-31
-12
-9
-5
-8
-18
147
137
271
909
418
1,046
-1
SEK 60 M pertained to goodwill that is attributable to strategic
advantages in the form of growth opportunities and a broader
product range. The costs of the acquisition amounted to SEK 2 M
and were charged to earnings for 2021 and 2022. Following the
acquisition, the company did not have any material impact on
Getinge's sales or earnings.
Fluoptics
In July 2022, 100% of the shares in Fluoptics SAS were acquired, a
France-based leader in fluorescence imaging as an aid to surgery.
The acquisition expands Getinge's customer offering in clinical
decision support, enhancing the safety and efficiency of operations.
Fluoptics has 29 employees and generated sales of SEK 45 M in
2022. The purchase price amounted to SEK 343 M, of which SEK 57 M
comprised contingent purchase prices that may be paid in 2024
if specific regulatory approvals are obtained and certain financial
targets achieved. The costs of the acquisition amounted to SEK 7 M
and were charged to earnings. The goodwill that arose in connection
with the acquisition amounted to SEK 211 M, and is primarily
attributable to strategic advantages pertaining to new technology
and sales-related synergies. The acquisition did not have any
material impact on Getinge's sales or earnings in the current year.
At the time of publication of this report, the acquisition analysis
was preliminary.
12
2
53
32
-100
-364
-18
365
715
Acquisitions in 2022
Irasun and Fluoptics were acquired during the period. In addition,
shares in the subsidiary Pulsion Medical Systems SE were acquired
for SEK 53 M, an additional purchase price of SEK 19 M was paid for
the acquisition of Quadralene and an amount of SEK 6 M was recei-
ved due to adjustments of working capital related to the acquisition
of Talis Clinical. The table above presents the fair value of acquired
identifiable net assets, recognized goodwill and the impact on the
Group's cash and cash equivalents.
Irasun
In January 2022, 100% of the German development company
Irasun GmbH, domiciled in Munich, were acquired. Irasun develops
products for venous drainage and temperature control, which can
be used in combination with heart-lung machines and equipment
for extracorporeal life support (ECLS). The products are not
yet commercially available but in the long term are intended to
strengthen the Group's offering in innovative solutions for surgical
perfusion. The purchase price amounted to SEK 75 M, of which
103View entire presentation